Efficacy and safety of treatments for metastatic castration-sensitive prostate cancer: A comprehensive network meta-analysis including final ARANOTE data

Abstract

This NMA supports the superior efficacy of ARPI combinations against ADT monotherapy, for both OS and PFS. While DAR + ADT demonstrated comparable efficacy to other doublet combinations, it offered a superior safety profile, making it an effective and safe option for managing patients with mCSPC.

Affiliated Institutions

• German Cancer Research Center DE
• University of Pittsburgh US
• Clifton Hospital GB
• Fundação Saúde BR
• University Health Network CA
• Bayer (Switzerland) CH
• Dana-Farber Cancer Institute US
• University of Toronto CA
• Pontificia Universidad Católica de Chile CL
• Mount Sinai Hospital CA
• Carolina Urologic Research Center US
• University of Warwick GB
• University of Bristol GB

Related Publications